Less than a year after a reorganization that included a headcount reduction and consolidation of sites, BridgeBio Pharma, Inc. may be on the upswing again as it reported Phase II data on 6 March for its achondroplasia candidate infigratinib that suggest superior efficacy to BioMarin Pharmaceutical Inc.’s Voxzogo (vosoritide) in improving growth rates for children with the genetic disorder also known as dwarfism. BridgeBio’s share price soared after the pre-market data release.
BridgeBio’s Achondroplasia Data Portend Competition With BioMarin’s Voxzogo
Already planning to position infigratinib as a safer, more convenient oral therapy for dwarfism compared with the BioMarin injectable, BridgeBio now has Phase II efficacy data showing a higher growth rate.
More from Clinical Trials
More from R&D
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?